Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.55 |
| ▸ | SLC5A1 | P13866 | 16/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4350692 | 0.87 | SLC5A2 (0.67) | SLC5A2SLC5A1 | |
| SCHEMBL4358723 | 0.86 | SLC5A2 (0.58) | SLC5A2SLC5A1 | |
| SCHEMBL4359584 | 0.85 | SLC5A2 (0.68) | SLC5A2SLC5A1 | |
| SCHEMBL5381328 | 0.83 | SLC5A2 (0.57) | SLC5A2SLC5A1 | |
| SCHEMBL5381324 | 0.81 | SLC5A2 (0.53) | SLC5A2SLC5A1 | |
| SCHEMBL3772111 | 0.81 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL2047708 | 0.81 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL3764258 | 0.78 | SLC5A2 (0.56) | SLC5A2SLC5A1 | |
| SCHEMBL3768818 | 0.78 | SLC5A2 (0.53) | SLC5A2SLC5A1 | |
| SCHEMBL14143691 | 0.78 | SLC5A2 (0.56) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655633-B2 | Beta-D-Glucopyranosyloxy)-3-(3-fluoro-4-methylbenzyl)-4,6-dimethylpyridine; sodium glucose co-transporter 2 (SGLT2) inhibitors; excellent hypoglycemic effect by excreting excess glucose into the urine through preventing the reabsorption of glucose at the kidney; antidiabetic agents; hyperglycemia | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-7655633-B2 | Beta-D-Glucopyranosyloxy)-3-(3-fluoro-4-methylbenzyl)-4,6-dimethylpyridine; sodium glucose co-transporter 2 (SGLT2) inhibitors; excellent hypoglycemic effect by excreting excess glucose into the urine through preventing the reabsorption of glucose at the kidney; antidiabetic agents; hyperglycemia | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-7655633-B2 | Beta-D-Glucopyranosyloxy)-3-(3-fluoro-4-methylbenzyl)-4,6-dimethylpyridine; sodium glucose co-transporter 2 (SGLT2) inhibitors; excellent hypoglycemic effect by excreting excess glucose into the urine through preventing the reabsorption of glucose at the kidney; antidiabetic agents; hyperglycemia | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20060035840-A1 | Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-16 | — | — | US | disclosed |
| EP-1577317-A1 | NITROGEN-CONTAINING HETEROCYCIC DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035840-A1 | Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof | SLC5A1, SLC5A2, SLC2A4 | SLC5A2 2/4885SLC5A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.